Skip to main content Help with accessibility Skip to main navigation

All Guidance

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - May - 2024

NHS England has advised CCGs that a prescription for the treatment of infrequent constipation should not routinely be offered in primary care as the condition is appropriate for self-care. The NHS England guidance applies to short term, infrequent constipation caused by changes in lifestyle or diet such as lack of water or movement or changes in diet. GPs should continue to prescribe laxatives to manage acute constipation with more complex aetiology (e.g. iatrogenic) and chronic constipation.

The NHS England guidance does not apply to the management of children and laxatives for children should continue to be prescribed by GPs.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 05 - December - 2023
BNF chapter: Respiratory system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - June - 2022
BNF chapter: Endocrine system

Advanced hormone-dependent prostate cancer with spinal metastases - to be read in conjunction with the SPC

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - December - 2022
BNF chapter: Central nervous system

To be read in conjunction with the SPC , NICE TA 217 and NICE CG42

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 18 - July - 2024

Denosumab 120mg injection - Prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.

Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 13 - February - 2024

Denosumab 60mg injection - Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of bone loss
associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2018

Denosumab as a second-line treatment option for the prevention of Osteoporotic Fragility Fractures

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 13 - February - 2024
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - May - 2024
BNF chapter: Cardiovascular system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - May - 2024
BNF chapter: Central nervous system

The Lancashire Medicines Management Group does not recommend the prescribing of e-Cigarettes

Adopted
Adopted
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Date Posted: 20 - September - 2023
BNF chapter: Genito-urinary system

This guidance includes a flow chart indicating a step-wise approach to the management of ED, with additional treatment notes that have been developed to guide prescribers

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 18 - October - 2023
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - October - 2017
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - November - 2022

Where a proprietary biological medicine is indicated and biologically similar (biosimilar) medicine(s) to the reference product also exist the product with the lowest acquisition price should be used and charged to the commissioning organisation at the acquisition price (within licensed indications).

Product choices, including changes to treatment, for individual patients should be made following assessment by the responsible clinician taking into account patient choice.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - May - 2024

LSCMMG has granted interim approval for this position statement ONLY. LSCMMG is aware that each locality, prior to the establishment of the ICB, had adopted the 'Over the counter items that should not be routinely prescribed in primary care policy'.

Interim approval has been granted to provide consistency of advice to prescribers whilst the ICB considers whether to adopt the 'Over the counter items that should not be routinely prescribed in primary care policy' across Lancashire and South Cumbria. 

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Date Posted: 20 - September - 2023
BNF chapter: Musculoskeletal system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 25 - April - 2024
BNF chapter: Central nervous system

Formerly the 'North West Headache Management Guideline for Adults'

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Pending
Date Posted: 13 - May - 2022
BNF chapter: Cardiovascular system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 14 - September - 2022
BNF chapter: Central nervous system

To be read in conjunction with the LSCMMG guideline ‘Assessing suitability of strong opioid use’